Form 4: Vaxcyte COO Jim Wassil Executes Stock Option and Sells Shares Under 10b5-1 Plan

Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 3, 2025, Jim Wassil, the Chief Operating Officer of Vaxcyte, Inc. (PCVX), exercised a stock option to acquire 8,000 shares of common stock at a price of $2.42 per share.
• Simultaneously, Wassil sold 5,314 shares at a weighted average price of $85.996, 2,666 shares at a weighted average price of $86.665, and 20 shares at $87.94.
• These sales were executed under a Rule 10b5-1 trading plan adopted on March 1, 2024.
• Following these transactions, Wassil directly owns 205,695 shares of Vaxcyte common stock and 2,638 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of insider transactions under a pre-arranged plan, which doesn't inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating that the sales were planned in advance and not based on insider information.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the existence of a 10b5-1 plan mitigates this concern.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions and provides transparency to the market regarding the trading activities of Vaxcyte's executives. It's common for executives to utilize 10b5-1 plans for managing their stock holdings.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a form of long-term incentive.
• The use of Rule 10b5-1 trading plans is a standard practice among corporate executives to avoid accusations of insider trading.
• Companies like Moderna (MRNA) and BioNTech (BNTX) also have executives who utilize similar trading plans.

Stakeholder Impact

• The stock sales may have a minor impact on shareholders, but the existence of a 10b5-1 plan suggests that the sales were planned and not based on any sudden change in the executive's outlook on the company.

Key Dates

Keywords

Vaxcyte, PCVX, Jim Wassil, stock options, Rule 10b5-1, insider trading, Form 4, stock sale, COO